Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 30
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Immunome Inc
IMNM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$18.21
-0.08
-0.44%
Dern. MÀJ: Oct 30, 6:47 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Immunome Financials
Immunome (IMNM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same
Benzinga Newsdesk
PRO
Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.57) by 15.79 percent. This is a 7.69 percent increase over losses of $(0.52) per share from the same
Benzinga Newsdesk
Immunome: Q4 Earnings Insights
Benzinga Insights
PRO
Immunome Q4 EPS $(0.75) Misses $(0.58) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.58) by 29.09 percent. This is a 41.41 percent increase over losses of $(1.28) per share from the
Benzinga Newsdesk
PRO
Immunome Q3 EPS $(0.65) Misses $(0.58) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.58) by 12.26 percent. This is a 16.67 percent increase over losses of $(0.78) per share from the
Benzinga Newsdesk
PRO
Immunome Q2 EPS $(0.50) Beats $(0.55) Estimate, Sales $4.015M May Not Be Comparable To $714.286K Estimate
Benzinga Newsdesk
